“Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s445. doi:10.25251/skin.8.supp.445.